Clinical trials
Phase 3 beta-Thalassemia trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
16 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 2 |
| 2021 | 1 |
| 2022 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 9 |
| Recruiting | 2 |
| Active, not recruiting | 1 |
| Terminated | 1 |
| Unknown status | 1 |
| Not yet recruiting | 1 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Vertex Pharmaceuticals Incorporated | 3 |
| Ain Shams University | 2 |
| Celgene | 2 |
| Genetix Biotherapeutics Inc. | 2 |
| Cerus Corporation | 1 |
| Consorzio per Valutazioni Biologiche e Farmacologiche | 1 |
| Hamad Medical Corporation | 1 |
| Hamdard University | 1 |
| Novartis | 1 |
| Novartis Pharmaceuticals | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| beta-Thalassemia | 16 |
| Thalassemia | 5 |
| Genetic Diseases, Inborn | 3 |
| Hematologic Diseases | 3 |
| Hemoglobinopathies | 3 |
| Anemia, Sickle Cell | 2 |
| Hemosiderosis | 2 |
| Iron Overload | 2 |
| Diabetes Mellitus | 1 |
| Hepatitis C | 1 |
Trials
Showing 51 to 16 of 16. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.